The present invention is directed to a method for predicting the risk of a female subject to develop postpartum HELLP syndrome, postpartum preeclampsia, or postpartum eclampsia. The method is based on the determination of the levels of i) sFlt-1 and PlGF, or ii) Endoglin and PlGF in a first sample obtained from said subject before delivery of baby, and a second sample of from said subject obtained after delivery of baby. Moreover, encompassed by the invention are devices and kits for carrying out the method of the present invention.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
An in-vitro diagnostic (IVD) analyzer 200 comprising an optical detection unit 217 comprising a cuvette 214 for the optical measurement of a biological sample 2, 2′ is herein disclosed. The IVD analyzer 200 further comprises a piezo actuator 218 arranged on one side of the cuvette 214 configured to transmit ultrasonic waves 254, 254′ through the cuvette 214, a piezo receiver 218′ arranged on the opposite side of the cuvette 214 configured to receive ultrasonic waves 255, 255′, 255″ transmitted through the cuvette 214 and a controller 250 configured to operate according to either a lysis operating mode (L) or an air-detection operating mode (AD). According to the lysis operating mode (L) the piezo actuator 218 is configured to transmit ultrasonic waves 254′ through the cuvette 214 for disrupting cellular particles contained in the biological sample 2. According to the air-detection operating mode (AD) the piezo actuator 218 is configured to transmit ultrasonic waves 254 through the cuvette 214 and the controller 250 is configured to correlate changes in amplitude and/or shifts of phase of the ultrasonic waves 255, 255′, 255″ received by the piezo receiver 218′ relative to reference values with an eventual presence and quantity of air 3 in the cuvette 214, in order to determine if the optical measurement of the biological sample 2, 2′ is affected by the presence of air 3. A respective automated method of operating the in-vitro diagnostic analyzer 200 in order to determine if the optical measurement of the biological sample 2, 2′ is affected by the presence of air is herein also disclosed.
A method of cross-flow filtering wastewater from a diagnostic apparatus or a laboratory analyser, wherein the wastewater comprises nanoparticles and/or microparticles, and the wastewater is streaming in a laminar flow across a surface of a filter membrane, the method comprising: (a) streaming the wastewater across the surface of the filter membrane with a flow rate, so that the flow of the wastewater is a laminar flow with a Reynolds number (Re) of smaller than 500; (b) streaming the wastewater in pulse cycles across the surface of the filter membrane, wherein each pulse cycle comprises one active phase in which the wastewater is under a duty pressure and one inactive phase in which the wastewater is under an inactive pressure, wherein the inactive pressure is no more than 10% of the duty pressure and the active phases have a duration of greater than 50% of the corresponding pulse cycles; and (c) separating the nanoparticles and/or microparticles from the wastewater when the wastewater passes through the filter membrane. Also described is a cross-flow filtration system configured for performing the method.
A healthcare data system. The system comprises a data protection entity configured to: sign at least a portion of a routing header of a data packet with a private key held by the data protection entity, the data packet including a payload and a routing header, the payload including healthcare data and the routing header indicating an intended consumer of the data packet; and transmit the data packet on towards the intended consumer. The healthcare data system further comprises one or more data receivers, each configured to: receive the data packet; and verify the signed routing header.
The present invention provides a novel monoclonal antibody specifically binding to L-Thyroxine (T4) and compositions and kits comprising such antibodies. Furthermore, provided are polynucleotides encoding such monoclonal antibodies, host cells expressing said antibodies, methods of producing such antibodies and diagnostic methods using such monoclonal antibodies. The monoclonal antibody of the invention comprises a heavy chain variable domain (VH) comprising V or A in position 33; Y in position 50; W in position 52; I in position 98, G, A or V in position 99; Y in position 100; and I in position 100b; and a light chain variable domain (VL) comprising amino acids H or Y in position 28; N or K in position 29; W in position 32; G or A in position 91; Y, W or F in position 92; S or T in position 93; Y or F in position 95b; N, S, T or Q in position 95c; and H in position 96, wherein the positions of the amino acids in the VH and the VL are indicated according to the Kabat numbering scheme, respectively.
An optical system configured for Fourier Ptychography is disclosed, comprising at least one array of light emitters, wherein each light emitter is configured for emitting at least one illumination light beam towards a sample plane; at least one lenslet array comprising a plurality of lenses, wherein each of the lenses is dedicated to at least one of the light emitters of the array of light emitters, wherein orientation and shape of the respective lens is adapted to the dedicated light emitter, wherein the lenslet array is configured for focusing the illumination light beams in the sample plane. The array of light emitters and the lenslet array are arranged such that the sample plane is illuminated by the illumination light beams under different illumination angles.
A computer implemented method for automated quality check of chromatographic and/or mass spectral data is disclosed. The method comprises the following steps:
a) (110) providing processed chromatographic and/or mass spectral data obtained by at least one mass spectrometry device (112);
b) (114) classifying quality of the chromatographic and/or mass spectral data by applying at least one trained machine learning model on the chromatographic and/or mass spectral data, wherein the trained machine learning model uses at least one regression model (116), wherein the trained machine learning model is trained on at least one training dataset comprising historical and/or semi-synthetic chromatographic and/or mass spectral data, wherein the trained machine learning model is an analyte-specific trained machine learning model.
An analytical system comprising a mass spectrometer and an ionization source. The analytical system further comprises an analytical fluidic system connectable to the ionization source for infusing samples into the mass spectrometer via the ionization source, a downstream pump fluidically connectable to the ionization source via the downstream valve, where the downstream pump is fluidically connected to a plurality of fluid containers comprising respective fluids, the fluids comprising a concentrated composition for calibrating the mass spectrometer and at least one diluent for diluting the at least one concentrated composition. The analytical system further comprises a controller configured to control the downstream pump to obtain at least one diluted composition by automatically mixing a concentrated composition with a diluent with a predetermined dilution factor, to infuse the diluted composition into the ionization source, to obtain a mass spectrum of the diluted composition and to execute a calibration of the mass spectrometer. A respective automated analytical method.
The present invention relates to a method for determining an analyte in a mass spectrometry (MS) device comprising a first and a second mass filter, said method comprising (i) filtering for an analyte ion species in the first mass filter; (ii) optionally fragmenting at least a fraction of ions obtained by the filtering in step (i) in a collision cell, wherein the collision energy of said fragmenting is selected to be lower than a predetermined collision energy causing fragmentation of said analyte ion species; (iii) filtering for said analyte ion species filtered for in step (i) in the second mass filter, and (iv) detecting said analyte ion species filtered for in step (iii), thereby determining said analyte. Moreover, the present invention relates to devices, systems, and uses related to said method.
The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
C07K 16/44 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel non prévu ailleurs
13.
METHODS AND SYSTEMS OF SAMPLE QUALITY VERIFICATION
A computer-implemented method for optimising an assignment of one or more medical samples to one or more analytical tests to be conducted on those medical samples. The method comprises the steps of: obtaining an initial assignment of the one or more medical samples to the one or more analytical tests; determining a compliance status for the or each medical sample, the compliance status indicating: (i) whether a sample quality metric of the or each medical sample violates an analytical test specification of the medical sample's assigned analytical test(s) in the initial assignment and/or (ii) whether the or each medical sample is unprocessable; and performing a mitigation action if one or more compliance status indicate: (i) that the sample quality metric of a given medical sample violates the analytical test specification and/or (ii) a given medical sample is unprocessable.
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p.ex. pour des analyses d’échantillon de patient
14.
TRANSPORT DEVICE AND LABORATORY SAMPLE DISTRIBUTION SYSTEM
The invention relates to a transport device for a laboratory sample distribution system, the transport device comprising a top cover having a transport surface, the transport surface being adapted to carry sample container carriers, an electromagnetic actuation assembly, the electromagnetic actuation assembly being adapted to generate a magnetic field at the transport surface for magnetic drive-interaction with a sample container carrier placed thereon, a support structure for carrying the actuation assembly, a sensor board being arranged in between the support structure and the top cover, the sensor board being adapted to detect a position of a sample container carrier placed on the transport surface with respect to the transport device, and elastic elements which are biased in between the sensor board and the support structure so that the sensor board is held flush against an inside surface of the top cover by a biasing force resulting from the biasing of the elastic elements.
B65G 54/02 - Transporteurs non mécaniques, non prévus ailleurs électrostatiques, électriques ou magnétiques
G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur
The present invention relates to a method for labeling an analyte in a sample, said method comprising (a) providing a detection agent binding to the analyte and conjugating said detection agent with an indicator agent to produce a conjugation product; (b) contacting said sample with said conjugation product of step (a); wherein said step (b) is performed directly after completion of step (a) and wherein steps (a) and (b) are performed by the same labeling device; and to labeling devices, systems, and uses related thereto.
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
The invention relates to an adjustable adapter for closing a c-shaped gap in between two modules of a laboratory system, the adjustable adapter comprising a base extending along a width direction (W) of the adjustable adapter, and a pair of legs each protruding from the base in a length direction (L) of the adjustable adapter so that the base and the legs are arranged in a c-shape of the adjustable adapter, the base being adjustable to set its dimension (D, D1, D2) along the length direction (L).
The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof specifically binding to Aβ42 with advantageous features for Aβ42 detection in vitro using immunoassays. Also provided is a polynucleotide or a set of polynucleotides encoding the same and a vector comprising said polynucleotide(s). Further provided is a host cell comprising the polynucleotide(s) and a corresponding production process using this host cell. Also provided herein are uses and methods employing the monoclonal antibody or an antigen-binding fragment thereof specifically binding to Aβ42 as provided herein.
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
There is provided an automatic analyzer equipped with a disk-type container placement mechanism, which enables an operator to perform additional placement of a container during analysis operation. The automatic analyzer includes a storage unit previously stored with a sample container 103 holding a sample before measurement of the sample, a dispensing mechanism 4 that sucks the sample from the sample container, an input unit that receives a command to store an emergency sample in the storage unit, the control unit 7 that controls such that, after a first operation being performed by the dispensing mechanism at a point of time when the command is received is completed, a second operation scheduled to be performed next by the dispensing mechanism is not started, and a display unit that prompts a user to store the emergency sample in the storage unit, in which the storage unit includes a first storage unit that stores an ordinary sample and a second storage unit that stores the emergency sample, and after controlling such that the second operation is not started, the control unit controls the second storage unit to move to a position where the emergency sample is inserted by a user.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
G01N 35/02 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p.ex. dispositifs d'aspiration, dispositifs d'injection
A system for securely storing data, such as sensitive personal data, including an interface configured with a REST API, an authentication module, at least one target database for storing the data, and a data access module which is configured to receive requests from a client computer by means of the interface, query data from the at least one target database in response to the received request, determine whether the client computer and/or the user has permission to query, and generate a response data set to respond to the request and transmit it to the client computer, wherein at least some data of the response data set is anonymised if restricted authentication is determined.
A method of determining the concentration of an analyte comprising: providing a sensor device comprising:
a field effect transistor having a source electrode, a drain electrode and a gate electrode,
a sensing electrode electrically connected or integrated into the gate electrode, and
a control device for applying operation parameters to the field effect transistor and for monitoring a signal value with the field effect transistor;
selecting a set of operation parameters of the field effect transistor, the selecting comprising performing evaluation measurements with the field effect transistor using various sets of operation parameter candidates and selecting a set in accordance with optimization criterion monitored during the evaluation measurements; and
detecting the concentration by applying the selected set of operation parameters to the field effect transistor and determining a signal value with the field effect transistor.
A method of determining the concentration of an analyte comprising: providing a sensor device comprising:
a field effect transistor having a source electrode, a drain electrode and a gate electrode,
a sensing electrode electrically connected or integrated into the gate electrode, and
a control device for applying operation parameters to the field effect transistor and for monitoring a signal value with the field effect transistor;
selecting a set of operation parameters of the field effect transistor, the selecting comprising performing evaluation measurements with the field effect transistor using various sets of operation parameter candidates and selecting a set in accordance with optimization criterion monitored during the evaluation measurements; and
detecting the concentration by applying the selected set of operation parameters to the field effect transistor and determining a signal value with the field effect transistor.
Further, a sensor device for determining the concentration of an analyte in a sample.
G01N 27/414 - Transistors à effet de champ sensibles aux ions ou chimiques, c. à d. ISFETS ou CHEMFETS
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
A laboratory apparatus comprising a housing, wherein the housing comprises a through-opening, wherein the through-opening is adapted for passing through it a transport device for transporting laboratory sample containers in and/or out of the housing, and a cover, wherein the cover comprises at least two ring segments, wherein the ring segments are adjustable to each other between a distant adjustment with at least one distance in between ends of the ring segments for arranging them around the passed through transport device and a near adjustment with less or no distance in between the ends of the ring segments for surrounding the passed through transport device, and wherein the cover in the near adjustment is adapted to cover a part of the through-opening left free by the passed through transport device, wherein the laboratory apparatus is a pre-analytical, analytical, and/or post-analytical laboratory apparatus, in particular a sorting module.
G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur
22.
MODIFIED ANTIBODY FOR SITE-SPECIFIC CONJUGATION AND ITS DIAGNOSTIC USE
The present invention relates to a modified antibody comprising a heavy chain and a light chain, wherein the antibody is modified to include in one or more of its immunoglobulin polypeptide chains one or more first recognition site(s) for the transglutaminase from Kutzneria albida (KalbTG) or a functionally active variant thereof. The one or more first recognition site(s) are introduced at one or more selected position(s) within an antibody's heavy chain and/or an antibody's light chain. The invention further relates to one or more nucleic acid(s) encoding an immunoglobulin polypeptide chain including the one or more recognition site(s), a site-specifically conjugated antibody comprising the modified antibody and one or more labelling domain(s) covalently attached to one or more first recognition sites, a kit for producing the conjugated antibody, a method of specifically labelling the modified antibody by way of site-specific conjugation, the use of the modified antibody for producing a specifically site-specifically conjugated antibody, a method of detecting a target in a sample and the use of the site-specifically conjugated antibody in the detection of a target and/or in the diagnosis.
C07K 16/40 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre des enzymes
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
The invention relates to a chute arrangement for a cap-removal apparatus, the cap removal apparatus being configured to remove caps from sample containers, the chute arrangement comprising a chute for transporting removed caps through a transport space of the chute arrangement, a sensor for detecting caps passing through a detection range of the sensor, the transport space being partially delimited by a chute bottom of the chute, the chute bottom being inclined with respect to gravity, the detection range protruding into the transport space, the detection range having a range border within the transport space, and the range border facing the chute bottom at a distance so that a bypass portion of the transport space is formed in between the chute bottom and the detection range.
The present invention relates to an in vitro method for cultivating one or more antibody expressing cell(s). The method comprises cultivating one or more antibody expressing cell(s) obtained from peripheral blood in the presence of IL-2, IL-21 and a non-cell surface presented CD40-stimulating agent and in the absence of feeder cells. Moreover, herein provided are methods for producing antibodies comprising the step of cultivating one or more antibody expressing cell(s) according to the method of the invention, a novel CD40-stimulating agent and uses therefrom as well as a cell culture medium.
A light source (112) for generating illumination light for illuminating at least one sample is disclosed. The light source (112) comprises
at least one array of light emitters (114), wherein each of the light emitters (114) is configured for emitting at least one light beam along a light beam path, wherein the light beam has a predefined wavelength range, and
at least one reflective optical grating (116) configured for overlaying the light beam paths, at least one transfer element (118);
wherein the transfer element (118) is arranged between the array of light emitters (114) and the optical grating (116) such that the transfer element (118) directs the emitted light beams onto the optical grating (116) and provides the light beams reflected from the optical grating (116) and impinging on the transfer element (118) into at least one measurement channel (120), wherein the measurement channel (120) is configured for receiving at least one sample.
G01N 21/359 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge en utilisant la lumière de l'infrarouge proche
G01N 21/33 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique en utilisant la lumière ultraviolette
G01N 21/3577 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge pour l'analyse de liquides, p.ex. l'eau polluée
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Chemical, biochemical and biological reagents for medical and diagnostic purposes; diagnostic reagents for clinical medical and diagnostic purposes; reagents for in-vitro laboratory use for medical purposes Medical apparatus, namely, clinical chemistry analyzers for use in the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for clinical medical diagnostic purposes
27.
TRANSFER DEVICE FOR TRANSFERRING SAMPLE CONTAINERS IN A SAMPLE HANDLING SYSTEM
A transfer device (110) for transferring sample containers in a sample handling system (112) is disclosed. The transfer device (110) comprises:
at least one transport device (114) comprising an array (116) of electromagnetic actuators (118), specifically electromagnetic actuators (118) comprising electromagnetic coils (120);
at least one moving unit (122) comprising at least one permanent magnet (124), wherein the moving unit (122) is movable in at least one movement plane (126), specifically in at least one movement plane (126) of the moving unit (122) defined by at least two moving directions (128), through the array (116) by magnetic interaction of the permanent magnet (124) with the electromagnetic actuators (118); and
at least one gripper unit (130) for positioning at least one of the sample containers, wherein the gripper unit (130) is movable in at least one gripping direction (132) essentially perpendicular to the movement plane (126), wherein the gripping unit (130) is attached to the moving unit (122).
A transfer device (110) for transferring sample containers in a sample handling system (112) is disclosed. The transfer device (110) comprises:
at least one transport device (114) comprising an array (116) of electromagnetic actuators (118), specifically electromagnetic actuators (118) comprising electromagnetic coils (120);
at least one moving unit (122) comprising at least one permanent magnet (124), wherein the moving unit (122) is movable in at least one movement plane (126), specifically in at least one movement plane (126) of the moving unit (122) defined by at least two moving directions (128), through the array (116) by magnetic interaction of the permanent magnet (124) with the electromagnetic actuators (118); and
at least one gripper unit (130) for positioning at least one of the sample containers, wherein the gripper unit (130) is movable in at least one gripping direction (132) essentially perpendicular to the movement plane (126), wherein the gripping unit (130) is attached to the moving unit (122).
Further disclosed is a sample handling system (112) for handling a plurality of sample containers and a method for transferring sample containers in a sample handling system (112).
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
The present invention relates to a method for determining an analyte of interest by frequency detection and the use thereof, a modified nanopore, an analyzing system, a kit and the uses thereof.
A computer-implemented method generates a message filter configuration based on a message priority indication of analytical device status messages received from a first analyzer network, the configuration based on identifying a type of analytical device status data associated with the message priority indication. The method includes communicating the message filter configuration, or a portion thereof, to a second analyzer network comprising a second analytical device.
H04L 47/24 - Trafic caractérisé par des attributs spécifiques, p.ex. la priorité ou QoS
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p.ex. pour des analyses d’échantillon de patient
H04L 43/062 - Génération de rapports liés au trafic du réseau
30.
METHOD AND SYSTEM FOR OPERATING A LABORATORY AUTOMATION SYSTEM
A method for operating a laboratory automation system, the laboratory automation system comprising a carrier comprising a reception place for receiving a sample container configured to contain a sample to be analyzed by a laboratory device; a placement device configured to pick and place the sample container; an imaging device; and a data processing device comprising at least one processor and a memory. The method comprises detecting an image of the reception place; determining whether the reception place is free for receiving the sample container and the reception place is configured to receive the sample container, by applying a machine learning algorithm for image analysis of the image of the reception place; and placing the sample container in the reception place by the placement device if the reception place is determined as free and configured to receive the sample container. Further, a laboratory automation system is disclosed.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p.ex. des objets vidéo
G06V 10/776 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p.ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]; Séparation aveugle de source Évaluation des performances
Classification of cell types A computer-implemented method of classifying cell types comprises: receiving image data representing a digital test image, the digital test image depicting a cell; applying a classifier model to the received image data, the classifier model configured to output a cell type of the cell depicted in the digital test image, wherein: the classifier model has been trained using training data comprising a plurality of digital records, each digital record comprising: training image data representing a digital training image depicting a cell; and a label indicative of the cell type of the cell depicted in the digital training image; and determining one or more digital reference images which depict cells most similar to the cell depicted in the digital test image; generating instructions which, when executed by a display component of a computing device, cause the display component to display: the cell type output by the classifier model; and the determined one or more digital reference images which depict cells most similar to the cell depicted in the digital test image. A corresponding diagnostic support and similar computer-implemented methods are also provided.
G06V 10/44 - Extraction de caractéristiques locales par analyse des parties du motif, p.ex. par détection d’arêtes, de contours, de boucles, d’angles, de barres ou d’intersections; Analyse de connectivité, p.ex. de composantes connectées
G06V 10/74 - Appariement de motifs d’image ou de vidéo; Mesures de proximité dans les espaces de caractéristiques
G06V 10/762 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant le regroupement, p.ex. de visages similaires sur les réseaux sociaux
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p.ex. des objets vidéo
G06V 10/778 - Apprentissage de profils actif, p.ex. apprentissage en ligne des caractéristiques d’images ou de vidéos
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G06V 10/94 - Architectures logicielles ou matérielles spécialement adaptées à la compréhension d’images ou de vidéos
G06F 18/21 - Conception ou mise en place de systèmes ou de techniques; Extraction de caractéristiques dans l'espace des caractéristiques; Séparation aveugle de sources
G06F 18/40 - Dispositions logicielles spécialement adaptées à la reconnaissance des formes, p.ex. interfaces utilisateur ou boîtes à outils à cet effet
A computer implemented method of a design enterprise network for facilitating remote configuration of a software instance comprised in a laboratory enterprise network, wherein the laboratory enterprise network is communicably coupled to an in vitro diagnostics (IVD) network, wherein the IVD network comprises at least one IVD instrument, and wherein the computer implemented method comprises obtaining by a generator computing instance comprised in a design enterprise network, a configuration definition input for configuring the software instance and generating, by the generator computing instance comprised in the design enterprise network, a configuration object based on the configuration definition input.
G16H 40/40 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion d’équipement ou de dispositifs médicaux, p.ex. pour planifier la maintenance ou les mises à jour
33.
HYDROPHILIC AZADIBENZOCYCLOOCTYNE DERIVATIVES AND METAL-FREE CLICK REACTIONS WITH THESE HYDROPHILIC AZADIBENZOCYCLOOCTYNE DERIVATIVES
The invention relates in a first aspect to an azadibenzocyclooctyne derivative according to formula (I) or a salt thereof having specific substituents at the benzo rings of the DIBAC structure and having specific substituents connected to the nitrogen atom of the DIBAC structure. A second aspect of the invention is directed to a conjugate of formula (II), wherein a substituent R6 is connected to the N atom of the 8 membered ring of the DIBAC structure via a linker structure —C(═O)-[L]n-Z—. A third aspect of the invention relates to a method for the modification of a target molecule, wherein a conjugate according to the second aspect is reacted with a target molecule comprising a 1,3-dipole group or a 1,3-(hetero)diene group. In a fourth aspect, the invention is directed to the use of the conjugate according to the second aspect for bioorthogonal labeling and/or modification of a target molecule. A fifth aspect of the invention relates to a modified target molecule comprising the reaction product of a conjugate according to the second aspect and a target molecule comprising a 1,3-dipole group or a 1,3-(hetero)diene group, obtained or obtainable from the method of the third aspect. In a sixth aspect, the invention is related to a kit comprising a modified target molecule according to the fifth aspect as detector reagent and a suitable capture reagent.
C07D 225/08 - Composés hétérocycliques contenant des cycles de plus de sept chaînons ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec des carbocycles ou avec des systèmes carbocycliques condensés avec deux cycles à six chaînons
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A computer-implemented method for processing electronic healthcare data, comprising: receiving, at an intermediate data processing device, a data packet from a data source, said data packet being for transmission to a data consumer across a network and including electronic healthcare data, said intermediate data processing device being connected between the data source and the data consumer in the network; performing, by the intermediate data processing device, a validation process of the data packet by comparison of the data packet to a healthcare data packet scheme; acknowledging, to the data source, receipt of a valid data packet at the intermediate data processing device from the data source when the data packet has been validated by the validation process; and transmitting the data packet on to the data consumer when the data packet has been validated by the validation process.
H04L 1/1607 - Dispositions pour détecter ou empêcher les erreurs dans l'information reçue en utilisant un canal de retour dans lesquelles le canal de retour transporte des signaux de contrôle, p.ex. répétition de signaux de demande - Détails du signal de contrôle
The invention relates to a laboratory sample container carrier handling apparatus comprising a revolving device and a guiding surface, wherein an entry segment of the guiding surface is adapted to smoothly receive a laboratory sample container carrier. The invention further relates to a laboratory automation system comprising such a laboratory sample container carrier handling apparatus and to a use of such a laboratory sample container carrier handling apparatus for handling a laboratory sample container carrier in, in particular such, a laboratory automation system.
G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur
The present invention relates to a method for assessing chronic liver disease in a subject, said method comprising (a) determining an amount of the biomarker Insulin-like growth factor-binding protein 3 (IGFBP3) in a sample from said subject; (b) determining an amount of the biomarker gamma-glutamyltransferase (GGT) in said sample; (c) comparing the amounts of the biomarkers determined in steps (a) and (b) to references for said biomarkers and/or calculating a score for assessing chronic liver disease; and (d) assessing chronic liver disease in said subject based on the comparison and/or the calculation made in step (c). The present invention further relates to computer-implemented methods, databases, devices, and uses related thereto.
C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une transférase
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
37.
Diagnostic System, Automatic Analyzer, and Diagnostic Method
To improve diagnostic accuracy of a sensor of an automatic analyzer. A diagnostic system for diagnosing a sensor that is provided in an automatic analyzer and outputs an analog electrical signal includes a memory that stores data of the electrical signal output by the sensor and a replacement history of the sensor, and a processing device that processes data recorded in the memory, in which the processing device reads, from the memory, data for a set reference period from among electrical signal data output by a past sensor that was used in the automatic analyzer, calculates a statistical value of the data for a reference period, reads, from the memory, data recorded during a set evaluation period from among electrical signal data output by a sensor for diagnosis that is being used in the automatic analyzer, calculates a statistical value of the data for an evaluation period, and determines an abnormality of the sensor for diagnosis based on a difference obtained from the statistical value of the reference period and the statistical value of the evaluation period.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
An in vitro method is disclosed for detecting an antibody to p53 (anti-p53 antibody) in a sample, the method comprising: incubating a sample to be analyzed with a p53 capture antigen and a p53 detection antigen, whereby a complex comprising the p53 capture antigen, the anti-p53 antibody and the p53 detection antigen is formed, separating the complex formed from unbound detection antigen and measuring the complex obtained via the detection antigen comprised therein, thereby detecting the anti-p53 antibody comprised in the sample.
G01N 33/564 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
The present invention relates to methods of assessing whether a patient has adenomyosis or is at risk of developing adenomyosis, to methods of selecting a patient for therapy of adenomyosis, and methods of monitoring a patient suffering from adenomyosis or being treated for adenomyosis, by determining the amount or concentration of sFRP4 in a sample of the patient, and comparing the determined amount or concentration to a reference.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/536 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec formation d'un complexe immunologique en phase liquide
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
A time tracking device (112) for monitoring system performance of at least one laboratory instrument is proposed. The time tracking device (112) comprises at least one support structure (114). The time tracking device (112) further comprises at least one electronics unit (116) and at least one motion sensor (118) housed by the support structure (114). The motion sensor (118) is configured for detecting a change of motion and/or orientation of the time tracking device (112). The electronics unit (116) is configured for measuring time, wherein a time measurement is initiated by detecting a change of motion and/or orientation of the time tracking device (112) and is terminated by detecting a subsequent change of motion and/or orientation of the time tracking device (112). The support structure (114) is a polygonal support structure (114) comprising a plurality of faces (120), wherein the support structure (114) comprises at least two interactive faces (136). Each of the interactive faces (136) comprises at least one user interface (138) comprising at least one display device (140). Each of the interactive faces (136) is configured for displaying at least one status indication (171) of the laboratory instrument, wherein the interactive face (136) matching a current status of the laboratory instrument is selectable by a user via changing motion and/or orientation of the time tracking device (112). The time tracking device (112) is con-figured for providing data relating to the measured time via at least one communication interface (172).
G04F 1/00 - Appareils pouvant être mis en marche et arrêtés pour mesurer des intervalles de temps prédéterminés ou choisis à volonté, sans mécanisme moteur, p.ex. sabliers
41.
APPARATUS FOR MEASURING A FILLING LEVEL OF A SAMPLE CONTAINER
The invention relates to an apparatus (1) for measuring a filling level of a sample container via laser transmission detection, the apparatus (1) comprising a laser source arrangement (2) for emitting light (L) of two distinctive wavelengths (A, B), a fiber optic (3) for guiding the light (L) emitted by the laser source arrangement (2), the fiber optic (3) extending from a first fiber portion (3) to a second fiber portion (5), the latter of which having a fiber ending (6) directed onto a target position (T) of the apparatus (1), such that a beam path (P) for light (L) leaving the fiber ending (6) is spanned toward the target position (T), a sample holder (7) for holding the sample container within the beam path (P), and a light transmission detector (D) for detecting light (L) reaching the target position (T) along the beam path (P), the light (L) reaching the target position (T) being transmitted by the sample container and/or a content thereof when placed within the beam path (P).
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p.ex. dispositifs d'aspiration, dispositifs d'injection
G01N 15/05 - Recherche de la sédimentation des suspensions de particules dans du sang
G01N 21/25 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes
42.
Effect induced by a sodium-glucose cotransporter inhibitor (SGLTi) in a subject suffering from a cardiovascular disease
The present invention relates to a method of detecting the effect induced by a sodium-glucose cotransporter inhibitor (SGLTi ) in a subject suffering from a cardiovascular disease, the method comprising a) determining the amount of Fatty Acid Binding Protein 3 (FABP3) in a sample of the subject treated with SGLTi; and b) comparing the amount of said FABP3 to a reference amountAlso encompassed are computer-implemented methods, computer program products, devices and kits for carrying out the method of the present invention. The present invention further relates to the use of FABP3, the use of FABP3 and a cardiac injury marker, and/or the use of a detection agent of FABP3 or FABP3 and a cardiac injury marker for detecting the effect induced by a sodium-glucose cotransporter inhibitor (SGLTi) in a subject suffering from a cardiovascular disease.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Chemical, biological and biochemical preparations for the analysis of biological samples for medical purposes; medical diagnostic assays and reagents for the analysis of biological samples for clinical or medical purposes; diagnostic reagents and preparations for medical purposes; in vitro diagnostic agents for the analysis of biological samples for medical purposes Analyzers for the analysis of biological samples for medical diagnostic purposes
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
Chemical, biological and biochemical preparations for the analysis of biological samples for medical purposes; medical diagnostic assays and reagents for the analysis of biological samples for clinical or medical purposes; diagnostic reagents and preparations for medical purposes; in vitro diagnostic agents for the analysis of biological samples for medical purposes Laboratory instruments for use in research and science, namely, analyzers for the analysis of biological samples for scientific or medical research use Analyzers for the analysis of biological samples for medical diagnostic purposes
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Chemical, biological and biochemical preparations for the analysis of biological samples for medical purposes; medical diagnostic assays and reagents for the analysis of biological samples for clinical or medical purposes; diagnostic reagents and preparations for medical purposes; in vitro diagnostic agents for the analysis of biological samples for medical purposes Analyzers for the analysis of biological samples for medical diagnostic purposes
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
Chemical, biological and biochemical preparations for the analysis of biological samples for medical purposes; medical diagnostic assays and reagents for the analysis of biological samples for clinical or medical purposes; diagnostic reagents and preparations for medical purposes; in vitro diagnostic agents for the analysis of biological samples for medical purposes Laboratory instruments for use in research and science, namely, analyzers for the analysis of biological samples for scientific or medical research use Analyzers for the analysis of biological samples for medical diagnostic purposes
An analyzer system (110) is disclosed. The analyzer system (110) comprises:
at least one mass spectrometry device (112) having at least one electrospray ion source nozzle (114);
at least one liquid supply (116), wherein the liquid supply (116) is configured for providing at least one liquid having at least one analyte;
at least one gas supply (118), wherein the gas supply (118) is configured for providing at least one gas; and
at least one dopand gas supply (120), wherein the dopand gas supply (120) is configured for providing at least one chemical dopand gas having at least one chemical dopand (122) to the analyte provided by the liquid supply (116);
wherein the liquid supply (116) and the gas supply (118) are coupled to the mass spectrometry device (112) via the electrospray ion source nozzle (114), wherein the dopand gas supply (120) is connected to the gas supply (118).
A method for operating a laboratory automation system, comprising, a transport system, a plurality of transfer devices; a portable device; and a plurality of data communication modules. The method comprises: receiving device information for the devices in the portable device, the device information being indicative a device identification; receiving a first user input in the portable device, the user input being indicative of a selection of a first device from the plurality of devices; in response to receiving the first user input, pairing the first device with the transport system for data communication in operation of the first device for at least one of sample pre-analytics and sample analysis; and providing first pairing information in the portable device, the first paring information being indicative of the first device and the distribution system being paired successfully. Further, a laboratory automation system and a laboratory in-vitro diagnostics system are provided.
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p.ex. pour des analyses d’échantillon de patient
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur
49.
AUTOMATIC REGISTRATION OF AT LEAST ONE DEVICE IN A LABORATORY SYSTEM
A computer-implemented method of automatic registration of a device in a laboratory system comprising:
transmitting from the to be registered device specific information to a managing unit (“unit”) via a first interface;
the unit requesting a solution specific configuration from a remote infrastructure via a second interface, receiving the solution specific configuration from the remote infrastructure via the second interface, and transmitting the solution specific configuration to the device to be registered via the first interface, the solution specific configuration being based on the device specific information and configuration information about the laboratory system; and
transmitting a request from the unit comprising updated solution specific configuration to the laboratory devices, the updated solution specific configuration comprising information about the device to be registered and changes due to addition of said device, wherein the laboratory configuration step comprising providing the updated solution specific configuration to the remote infrastructure.
G16H 40/40 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion d’équipement ou de dispositifs médicaux, p.ex. pour planifier la maintenance ou les mises à jour
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
Laboratory instruments, namely, clinical chemistry analyzers and immunochemistry analyzers for the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for scientific or medical research purposes; computer hardware and downloadable software for use with laboratory instruments, namely, for use in data analysis and database management Medical apparatus, namely, clinical chemistry analyzers and immunochemistry analyzers for use in the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for clinical medical diagnostic purposes
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
Laboratory instruments, namely, clinical chemistry analyzers and immunochemistry analyzers for the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for scientific or medical research purposes; computer hardware and downloadable software for use with laboratory instruments, namely, for use in data analysis and database management Medical apparatus, namely, clinical chemistry analyzers and immunochemistry analyzers for use in the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for clinical medical diagnostic purposes
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
Laboratory instrument for the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for use in research, science and industry; computer hardware and downloadable software for use with laboratory instruments, namely, for use in providing automation of laboratory processes, control and monitoring of laboratory instruments, connectivity, data analysis, and data management Medical apparatus for the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for medical diagnostic purposes
53.
STREM1 MARKER PANELS FOR EARLY DETECTION OF SEPSIS
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being STREM1, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: Aspartate aminotransferase, Bilirubin, ESM-1, HBP (Heparin-binding protein), a cardiac Troponin, Alanine aminotransferase, and IL6, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being STREM1 and a second biomarker selected from the group consisting of: Aspartate aminotransferase, Bilirubin, ESM-1, HBP (Heparin-binding protein), a cardiac Troponin, Alanine aminotransferase, and IL6 or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
54.
SUPPLEMENTING MEASUREMENT RESULTS OF AUTOMATED ANALYZERS
A system for supplementing measurement results of automated analyzers is presented. The system includes a computer device configured for obtaining a result of a measurement performed by an automated analyzer, the computer device and the automated analyzer being located within a privileged computer network, obtaining a context related algorithm associated with the result of the measurement defining one or more triggering conditions and context related information from a computer device residing outside of the privileged computer network at the computer device and processing the result of the measurement by using the context related algorithm to generate a context specific supplement to the result of the measurement at the computer device.
G06F 17/18 - Opérations mathématiques complexes pour l'évaluation de données statistiques
G06F 21/62 - Protection de l’accès à des données via une plate-forme, p.ex. par clés ou règles de contrôle de l’accès
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p.ex. pour des analyses d’échantillon de patient
G16H 40/67 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement à distance
The present invention relates to diagnostic test and technology. In particular, the present invention relates to a method for determining an analyte suspected to be present in a sample comprising contacting said sample with a sensor element comprising i) an anchor layer which is present on a solid support, ii) a first binding agent which is capable of specifically binding to the analyte, which is anchored in the anchor layer and which comprises at least one detectable label, and iii) a second binding agent which is capable of specifically binding to the analyte when bound to the first binding agent and which is immobilized on the solid support, for a time and under conditions which allow for specific binding of the analyte suspected to be present in the sample to the first binding agent and specific binding of the second binding agent to the analyte bound to the first binding agent and detecting the formation of the complex of first binding agent, analyte and second binding agent whereby the analyte is determined. Moreover, provided is a device for determining an analyte suspected to be present in a sample and the use thereof for determining an analyte suspected to be present in a sample in said sample. Moreover, the present invention contemplates a kit for determining an analyte suspected to be present in a sample.
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
The present invention relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being GDF-15, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: sFLT1, Cystatin C, IGFBP-7, Bilirubin, ESM-1, sTREM-1, Procalcitonin, cardiac Troponin, BNP-type peptide, Alanine aminotransferase, and Aspartate aminotransferase, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being GDF-15 and a second biomarker selected from the group consisting of sFLT1, Cystatin C, IGFBP-7, Bilirubin, ESM-1, sTREM-1, Procalcitonin, cardiac Troponin, BNP-type peptide, Alanine aminotransferase, and Aspartate aminotransferase or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/573 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour enzymes ou isoenzymes
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being sFlt1, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: Cystatin C, IGFBP7, a cardiac Troponin, Creatinine, STREM1, PCT and Bilirubin, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being sFltl and a second biomarker selected from the group consisting of: Cystatin C, IGFBP7, a cardiac Troponin, Creatinine, sTREM1, PCT and Bilirubin, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une transférase
C12Q 1/52 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une transférase une transaminase
G01N 33/70 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir la créatine ou la créatinine
G01N 33/72 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir les pigments du sang, p.ex. l'hémoglobine, la bilirubine
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being ESM-1, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is Creatinine or a Cystatin C, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being ESM-1 and a second biomarker being Creatinine or a Cystatin C or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
C12Q 1/52 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une transférase une transaminase
G01N 33/72 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir les pigments du sang, p.ex. l'hémoglobine, la bilirubine
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
59.
METHODS OF RECOMBINANTLY PRODUCING NEUTRAL PROTEASE ORIGINATING FROM PAENIBACILLUS POLYMXA
The present disclosure provides the sequence of a Paenibacillus polymyxa preproenzyme which is the precursor of a neutral protease, expression thereof in a transformed host organism, and methods for production of the neutral protease, by recombinant means. Further, use of the recombinantly produced neutral protease is disclosed in the field of cell biology, particularly for the purpose of tissue dissociation. The disclosure also includes blends with other proteases. Further disclosed are nucleotide sequences encoding the neutral protease.
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being PCT, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a cardiac Troponin, Creatinine, a BNP-type peptide, sTREM1, ESM-1, Haptoglobin, Heparin binding protein (HBP) and Aspartate aminotransferase, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being PCT and a second biomarker selected from the group consisting of: a cardiac Troponin, Creatinine, a BNP-type peptide, sTREM1, ESM-1, Haptoglobin, Heparin binding protein (HBP) and Aspartate aminotransferase, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/70 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir la créatine ou la créatinine
G01N 33/72 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir les pigments du sang, p.ex. l'hémoglobine, la bilirubine
G01N 33/74 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des hormones
61.
IGFBP7 MARKER PANELS FOR EARLY DETECTION OF SEPSIS
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being IGFBP7, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: PCT, IL6, a cardiac Troponin, Albumin, CRP, Bilirubin, Ferritin, ESM-1, Aspartate aminotransferase, a BNP-type peptide, Alanine aminotransferase, Creatinine, and suPAR, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being IGFBP7 and a second biomarker selected from the group consisting of: PCT, IL6, a cardiac Troponin, Albumin, CRP, Bilirubin, Ferritin, ESM-1, Aspartate aminotransferase, a BNP-type peptide, Alanine aminotransferase, Creatinine, and suPAR, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
62.
METHOD FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST
The present invention relates to a method for determining at least one analyte of interest. The present invention further relates to a sample element, an inlet, a composition, a kit and the use thereof for determining at least one analyte of interest.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
63.
INFORMATION PROCESSING DEVICE FOR PROVIDING REFERENCE INFORMATION RELATING TO DIAGNOSIS OF THYROID DISEASE
An information processing device includes a first determination unit that inputs information related to total protein (TP), cholinesterase (ChE), total cholesterol (TC), creatinine (CREA), and creatine phosphokinase (CPK) to a first learning-completed model based on information related to a blood examination of a subject and outputs information related to whether thyroid stimulation hormone (TSH) of the subject is in a range for which medical treatment is needed.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/70 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir la créatine ou la créatinine
G01N 33/92 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des lipides, p.ex. le cholestérol
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being IL-6, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is Creatinine or a cardiac Troponin, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being IL-6 and a second biomarker being a cardiac Troponin or Creatinine or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/70 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir la créatine ou la créatinine
A first aspect of the invention is related to the use of a (poly)label for generating a quantifiable signal for an analyte of interest in mass spectrometry, wherein the (poly)label has the structure (I). In a second aspect, the invention is directed to a process for modifying an analyte of interest for obtaining an increased intensity signal in mass spectrometry. A third aspect of the invention is directed to a method for determining an analyte of interest by mass spectrometry. A fourth aspect of the invention relates to a (poly)label having structure of formula (Ia). In a fifth aspect, the invention is related to a reaction product comprising a polypeptide and a (poly)label having the general structure (III).
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
This automated analysis device comprises a first analyzing unit for performing analysis related to a first analysis item group, a second analyzing unit for performing analysis of a second analysis item group using a measuring principle different from the first analyzing unit, a reagent storage unit for storing at least one first reagent vessel accommodating a reagent used for the analysis by the first analyzing unit and at least one second reagent vessel for accommodating a reagent used for the analysis by the second analyzing unit, an agitating unit for agitating a solution in the second reagent vessel, and a control unit for controlling operation of the agitating unit, wherein the control unit controls the operation of the agitating unit to agitate a solution in the first reagent vessel. This makes it possible to agitate a plurality of reagents used for a plurality of measurements that employ different principles, while suppressing an increase in the size of the device.
G01N 35/02 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
67.
SOLID PHASE PEPTIDE SYNTHESIS (SPPS) SOLVENT SYSTEM
The present invention relates to a solid phase peptide synthesis (SPPS) solvent system and use thereof. The present invention further relates to a solid phase peptide synthesis (SPPS), a kit, a peptide synthesizer and the use thereof.
The present invention relates to an instrument for automatically removing sealing covers from sample vessels (and/or for automatically sealing or resealing sample vessels with sealing covers, the instrument comprising a vessel holder for holding a sample vessel, and a suction/induction device comprising a suction member for holding a sealing cover, and an induction member comprising at least one induction coil, with the suction/induction device and the vessel holder being arranged in an axially movable manner with regard to each other, and, in use, the at least one induction coil is arranged above a bottom of the suction member. In addition, the present invention relates to a laboratory automation system comprising such instrument as well as a plurality of pre-analytical, analytical and/or post-analytical stations, and also relates to a method of automatically removing sealing covers from sample vessels and a method of automatically sealing or resealing sample vessels with sealing covers.
B01L 9/00 - Dispositifs de support; Dispositifs de serrage
B01L 9/06 - Supports de tubes à essai; Porte-tubes à essai
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
69.
METHOD OF WASHING A FLUIDIC SYSTEM OF AN IN-VITRO DIAGNOSTIC ANALYZER
An automated method of washing a fluidic system 210 of an IVD analyzer 200 from a previous fluid is disclosed, the fluidic system 210 comprising at least one fluidic path 211, 213, 215. The method comprises controlling by a controller 250 a pump 240 and at least one fluid-selection valve 230 for pumping a wash fluid 221 and/or air 232 through the at least one fluidic path, wherein in a time-priority mode 10 the method comprises pumping at higher speed air, in a first step 11, in order to remove the previous fluid from the at least one fluidic path, and wash-fluid plugs alternated to air plugs, in a second step 12, in order to wash out residuals of the previous fluid, and wherein in a wash-fluid-priority mode 20 the controller 250 is configured to operate according to either a sample-wash mode 30 if the previous fluid is a sample 2 or according to an other-fluid-wash mode 40 if the previous fluid is any fluid other than a sample 2, wherein in the sample-wash mode 30 the method comprises pumping air at lower speed, in a first step 31, in order to remove the previous fluid from the at least one fluidic path, pumping at least one wash-fluid plug at higher speed, in a second step 32, and pumping wash-fluid plugs alternated to air plugs at lower speed, in a third step 33, in order to wash out residuals of the previous fluid, and wherein in the other-fluid-wash mode 40 the method comprises pumping air at lower speed, in a first step 41, in order to remove the previous fluid from the at least one fluidic path and pumping wash-fluid plugs alternated to air plugs at lower speed, in a second step 42, in order to wash out residuals of the previous fluid.
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p.ex. dispositifs d'aspiration, dispositifs d'injection
B08B 9/032 - Nettoyage de conduites ou de tubes ou des systèmes de conduites ou de tubes Élimination des bouchons par l'action mécanique d'un fluide en mouvement, p.ex. par effet de chasse d'eau
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
A method for automated microscopic scanning is disclosed. The method comprises the following steps: a. (110) image data acquisition, wherein the image data acquisition comprises generating microscopic images of a sample by scanning at least one pre-defined scanning area of at least one microscopic slide (128)carrying the sample by using at least one image scanner (122); b. (112) determining at least one feature characterizing at least one biological entity of the sample by applying at least one classification algorithm to the microscopic images by using at least one processing device, wherein the feature is compared to at least one pre-defined criterion, wherein the determining and the comparing is performed in parallel to the image data acquisition, wherein the image data acquisition of said microscopic slide (128) is discontinued by at least one controlling device of the image scanner (122) as soon as the determined feature reaches the pre- defined criterion; and c. repeating the method for a next microscopic slide (128).
The present disclosure refers to a method for operating an in-vitro-diagnostics laboratory system, IVD laboratory system. The IVD laboratory system has a housing (12) with an opening (12a); an actuator device (10), arranged in the housing (12), for processing sample containers; a cover (11) configured to cover the opening (12a); a cooling device (14) configured to cool the sample containers; and a cooling device control unit (15) configured to control operation of the cooling device (14). The method comprises: determining whether the cover (11) is open; determining whether the cooling device control unit (15) is active; in a normal system mode, disabling operation of the actuator device (10) based on at least one of the cover (11) being open and the cooling device control unit (15) being inactive; and in a bypass system mode, enabling operation of the actuator device (10) based on the cover (11) being open and the cooling device control unit (15) being active.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p.ex. pour des analyses d’échantillon de patient
G16H 40/20 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion ou l’administration de ressources ou d’établissements de soins de santé, p.ex. pour la gestion du personnel hospitalier ou de salles d’opération
The invention relates to a method of operating a gripping device (100) being adapted to insert sample containers (1) into sample container racks (2) and/or remove sample containers (1) from sample container racks (2), wherein the gripping device (100) comprises gripping fingers (3) being adapted to grip the sample containers (1), wherein the method comprises the steps: moving the gripping fingers (3) in z-direction to insert a sample container (1) into a sample container rack (2) or remove a sample container (1) from a sample container rack (2), determining, if the gripping fingers (3) get in contact with the sample container rack (2), and performing an error procedure, if the gripping fingers (3) get in contact with the sample container rack (2).
B25J 15/08 - Têtes de préhension avec des éléments en forme de doigts
B25J 19/00 - Accessoires adaptés aux manipulateurs, p.ex. pour contrôler, pour observer; Dispositifs de sécurité combinés avec les manipulateurs ou spécialement conçus pour être utilisés en association avec ces manipulateurs
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
73.
DETECTION OF AN ANALYTE OF INTEREST BY A CHIP BASED NANOESI DETECTION SYSTEM
The present invention relates to a method, a diagnostic system, a kit and the use thereof for efficiently detection of an analyte of interest by a chip based nanoESI detection system.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
74.
DERIVATISATION AGENT FOR LASER DESORPTION IONIZATION MASS SPECTROMETRY
In a first aspect, the invention relates to a derivatisation agent, preferably derivatisation agent for analytes intended to be analysed via LDI-MS, comprising a structural element of formula (I) C- L1 -Z - (L2)p - X, wherein C is a chromophore having an absorption maximum in the range of from 280 to 400 nm; Z is a charged unit comprising at least one permanently charged moiety; X is a reactive group; L1, L2 are each a linker unit; and p is either zero or 1. A second aspect of the invention is related to a kit comprising the derivatisation agent according to the first aspect. In a third aspect, the invention is directed to a use of the derivatisation agent according to the first aspect for the mass spectrometric determination of an analyte molecule, wherein the mass spectrometric determination is LDI-MS. A fourth aspect of the invention relates to a conjugate of a derivatisation agent according to the first aspect and an analyte, wherein the conjugate has the structure of formula (II) C- L1 - Z - (L2)p - Xa - Ya - A, wherein C, L1, L2, p, Z and N are as defined in the context of the first aspect; Xa is a remainder of a reactive group X as defined in the context of the first aspect; A is the analyte and Ya is the remainder of a reactive group Y bound to the analyte A, which has reacted with the reactive group X of the derivatisation agent thus forming a covalent bound between Xa and Ya. A fifth aspect of the invention is related to a method for the mass spectrometric determination of an analyte molecule comprising the steps: (a) providing an analyte of interest; (b) providing a derivatisation agent comprising a structure of formula (I) as defined in the context of the first aspect; (c) reacting the analyte provided according to (a) with the derivatisation agent provided according to (b), whereby a conjugate of the analyte and the derivatisation agent is formed, and (d) subjecting the conjugate formed in (c) to a mass spectrometric analysis, wherein the mass spectrometric analysis is preferably LDI-MS.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/74 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des hormones
75.
METHOD FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST
The present invention relates to a method for determining at least one analyte of interest and the uses thereof. The present invention further relates to a diagnostic system, a kit and the use thereof for determining at least one analyte of interest.
A method for detecting at least one analyte (110) in a sample (112) is disclosed. The method comprises the following steps:
a) providing at least one sample (112) having at least one analyte (110);
b) incubating the sample (112) with microparticles (118) having at least one surface (120) whereby the analyte (110) is adsorbed on the surface (120) of the microparticles (118) and an analyte-microparticle-complex (122) is formed;
c) providing at least one fiber sheet material (128) having at least one tip (130) and contacting the tip (130) of the fiber sheet material (128) to the sample (112) comprising the analyte-microparticle-complex (122), whereby at least the analyte-microparticle-complex (122) is sucked into the tip (130) of the fiber sheet material (128);
d) contacting the tip (130) of the fiber sheet material (128) to a port of an analytical device;
e) adding an extracting solvent (138) to the fiber sheet material (128) and applying an electrical voltage to the fiber sheet material (128) whereby ions of the analyte (110) are generated and are expelled from the tip (130) of the fiber sheet material (128); and
f) detecting the at least one analyte (110) with the analytical device (134).
The present invention generally relates to the field of isotope labeled and non-labeled gentamicin congeners and synthetic methods for the preparation of such congeners. In particular, the present invention relates to isotope labeled gentamicin C or a salt or solvate or derivative thereof, the gentamicin C comprising at least one 13C, D and/or 15N atom and methods for the preparation of gentamicin C or salt or solvate or derivate thereof, in particular of gentamicin C comprising at least one 13C, D and/or 15N atom or salt or solvate or derivate thereof.
C07H 15/236 - Cycles cyclohexane substitués par au moins deux atomes d'azote avec au moins deux radicaux saccharide directement liés aux cycles cyclohexane liés à des atomes de carbone non adjacents des cycles cyclohexane, p.ex. kanamycines, tobramycine, nebramycine, gentamycine A2 un radical saccharide étant substitué par un radical alkylamino en position 3 et par deux substituants autres que l'hydrogène en position 4, p.ex. complexe de gentamicine, sisomicine, verdamicine
C07H 1/00 - Procédés de préparation des dérivés du sucre
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p.ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
78.
SECURE COLLABORATIVE LABORATORY DATA ANALYTICS SYSTEM
A method of creating a secure collaborative analysis system for securely using a dataset from a plurality of laboratories (150) while ensuring confidentiality, integrity, and authenticity of input and result data among the plurality of collaborating laboratories (150) is presented. The plurality of laboratories (150) are communicatively connected to an execution environment. The method comprise creating a secure enclave (110) within the execution environment for data exchange and analysis, attestation of the execution environment and the secure enclave (110) to verify integrity and authenticity of the system, generating a random 12-byte character inside the secure enclave (110) to provide integrity protection for storing records in a database (130), and building a communication component to provide a means of secure communication between the plurality of laboratories (150) and the execution environment. The communication component comprises a trusted section within the secure enclave (110) and an unprotected section. The plurality of laboratories (150) communicate with the trusted part via a secure channel. The method further comprises detecting any unauthorized modification to the record stored in the database (130) outside of the secure enclave (110) by a records integrity component, storing the encrypted dataset in the persistent storage disk (120) received from the plurality of laboratories (150), retrieving the encrypted dataset inside the secure enclave (110), decrypting the encrypted dataset inside the secure enclave (110), providing the decrypted dataset to an analysis engine component within the secure enclave (110) for analysis, and providing results of that analysis to plurality of laboratories (150) in the secure manner.
The present invention relates to diagnostic test and technology. In particular, the present invention relates to a method for determining an analyte suspected to be present in a sample comprising (a) contacting said sample with (i) a first binding agent which is capable of specifically binding to the analyte and which is immobilized on a solid support and (ii) a second binding agent which is capable of specifically binding to the analyte and which is capable of reversibly binding at least one detectable label, wherein said first and/or second binding agent is linked to an linking agent which is capable of covalently binding the at least one reversibly bound detectable label to the solid support when the first and second binding agents are in physical proximity, for a time and under conditions which allow specific binding of the analyte to the first and the second binding agent such that an complex of first binding agent, analyte and second binding agent is formed, and which allow for covalently binding the at least one detectable label to the solid support, and (b) removing the complex of first binding agent, analyte and second binding agent from the solid support such that the solid support having covalently bound the at least one detectable label remains, and (c) detecting the at least one covalently bound detectable label on the solid support whereby the analyte is determined. The present invention also relates to a device for determining an analyte suspected to be present in a sample, to the use of the device of the invention for determining an analyte suspected to be present in a sample in said sample, and to a kit for determining an analyte suspected to be present in a sample.
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
80.
METHOD FOR IMMUNOSENSING ON A LIPID LAYER USING MAGNETIC TUNNEL JUNCTIONS II
The present invention concerns the field of diagnostics. In particular, it relates to a method for determining an analyte suspected to be present in a sample comprising contacting said sample with a sensor element comprising an anchor layer which is present on a solid support, a first binding agent which is capable of specifically binding to the analyte, which is anchored in the anchor layer, a second binding agent which is capable of specifically binding to the analyte when bound to the first binding agent and which is immobilized on the solid support, said second binding agent comprising at least one magnetic label, and a magnetic tunnel junction in functional proximity to the second binding agent which generates a signal elicited in proximity to the at least one magnetic label of the second binding agent, for a time and under conditions which allow for specific binding of the analyte suspected to be present in the sample to the first binding agent and specific binding of the second binding agent to the analyte bound to the first binding agent and detecting the formation the complex of first binding agent, analyte and second binding agent based on an altered signal which is generated by the magnetic tunnel junction whereby the analyte is determined. The present invention, further, relates to a device and a kit for determining an analyte suspected to be present in a sample and to the use of said device for determining an analyte suspected to be present in a sample.
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01R 33/09 - Mesure de la direction ou de l'intensité de champs magnétiques ou de flux magnétiques en utilisant des dispositifs galvano-magnétiques des dispositifs magnéto-résistifs
81.
TARGET FOR USE IN A LASER DESORPTION MASS SPECTROMETER
A target (110) for use in a laser desorption mass spectrometer is disclosed. The target (110) has at least one surface (112). wherein the surface (112) is covered at least partially with at least one layer (114), wherein the layer (114) is a hydrogen comprising, silicon-incorporated amorphous carbon (a-C:H:Si) layer (116), wherein the a-C:H:Si layer (116) comprises:
40 at. % to 80 at. % of carbon;
1 at. % to 20 at. % of hydrogen; and
10 at. % to 40 at. % of silicon.
The present invention relates to a method of determining an analyte in a sample, said method comprising (a) contacting said sample with (i) a binding compound binding to said analyte, said binding compound comprising a binding agent and a first partner of an affinity pair (first affinity partner); and (ii) a second partner of the affinity pair (second affinity partner) coupled to a solid surface, to an indicator, and/or to a second binding agent; and (b) determining said analyte based on complexes formed in step (a); wherein one of said first affinity partner and said second affinity partner is a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a sequence at least 50% identical thereto, and wherein the other of said first affinity partner and said second affinity partner is a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or a sequence at least 50% identical thereto. The present invention also relates to a polypeptide comprising an amino acid sequence as specified in SEQ ID NO:1 or a sequence at least 50% identical thereto, wherein the amino acid at the position corresponding to position 77 in SEQ ID NO:1 is not a histidine; and to a polypeptide comprising an amino acid sequence as specified in SEQ ID NO:2 or a sequence at least 50% identical thereto, wherein (i) the amino acid at the position corresponding to position 17 in SEQ ID NO:2 is not a cysteine, in an embodiment is alanine, serine, leucine, isoleucine, or glycine and/or (ii) said polypeptide further comprises at least one functional peptide; and to fusion polypeptides, polypeptide complexes, polynucleotides and kit related to the aforesaid.
C07K 14/195 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
A sample carrier transport device (116) for transporting sample carriers (110) to a work- station (112) for sample processing is disclosed. The sample carrier transport device (116) comprises a surface (128) having a plurality of sample carrier holder portions (130). Each of the sample carrier holder portions (130) is configured for removably holding at least one sample carrier (110) during transport of the sample carrier (110) to the workstation (112). The surface (128) is configured for performing a movement for transporting the sample carrier (110) to the workstation (112). The sample carrier transport device (116) comprises at least one lifting mechanism configured for moving the surface (128) to at least one transport position and to at least one transfer position. The transport position and the transfer position refer to different heights of the surface (128). The lifting mechanism is configured for holding the surface (128) during transport of the sample carriers (110) to the workstation (112) in the transport position. The sample carrier transport device (116) is configured for handing over the sample carrier (110) to the workstation (112) and for receiving the sample carrier (110) from the workstation (112) in the transfer position.
G01N 35/02 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse
84.
CLINICAL SUPPORT SYSTEM AND ASSOCIATED COMPUTER-IMPLEMENTED METHODS
A clinical support system comprises a processor and a display component, wherein: the processor is configured to: receive image data, the image data representing an image of a plurality of cells obtained from a human or animal subject, the image data comprising a plurality of subsets of image data, each subset comprising data representing a portion of the image data corresponding to a respective cell of the plurality of cells; apply a trained deep learning neural network model to each subset of the image data, the deep learning neural network model comprising: a plurality of convolutional neural network layers each comprising a plurality of nodes; and a bottleneck layer comprising no more than ten nodes, wherein the processor is configured to apply the trained deep learning neural network model to each subset of the image data by applying the plurality of CNN layers, and subsequently applying the bottleneck layer, each node of the bottleneck layer of the machine-learning model configured to output a respective activation value for that subset of the image data; for each subset of the image data, derive a dataset comprising no more than three values, the values derived from the activation values of the nodes in the bottleneck layer; and generate instructions, which when executed by the display component of a clinical support system, cause the display component of the computer to display a plot in no more than three dimensions of the respective dataset of each subset of the image data. Associated computer-implemented methods, including for training the deep learning neural network model, are provided.
G06T 11/20 - Traçage à partir d'éléments de base, p.ex. de lignes ou de cercles
G06V 10/774 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p.ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]; Séparation aveugle de source méthodes de Bootstrap, p.ex. "bagging” ou “boosting”
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G16B 15/00 - TIC spécialement adaptées à l’analyse de structures moléculaires bidimensionnelles ou tridimensionnelles, p.ex. relations structurelles ou fonctionnelles ou alignement de structures
FILTRATION SYSTEM, METHOD FOR PREDICTING A MAINTENANCE CONDITION OF THE FILTRATION SYSTEM AND METHOD FOR PREDICTING A RECOVERY CONDITION OF THE FILTRATION SYSTEM
A method for predicting a maintenance condition of a filtration system of a diagnostic apparatus or a laboratory analyser at a given time is done by performing the following steps. First a plurality of successive raw permeability values of the permeability of a fluid through the filtration device over a specified measurement period is measured. Then smoothed permeability values are determined by means of a data processing method to reduce the fluctuations of the raw permeability values over time. Afterwards a regression analysis function is applied through the successive permeability values, wherein the regression analysis function comprises fitting parameters being adapted so that the fitting function is fitted to the measured permeability values. Finally, the time, when the regression analysis function will cross a predetermined threshold value is determined, wherein the crossing of the threshold value is judged as a maintenance condition.
Detection of abnormality in specimen image A computer-implemented method of detecting the presence of morphologically abnormal cells in a specimen image comprises: receiving electronic image data representative of a specimen image, the specimen image depicting a plurality of cells; applying an analytical model to each of a plurality of subsets of the image data, each subset corresponding to a respective portion of the specimen image which depicts a single cell, the analytical model configured to output, for each subset of the image data: a value parameterizing a property of the cell; and either a confidence score or an uncertainty score associated with the value, thereby generating output data comprising the plurality of confidence scores or plurality of uncertainty scores; and determining, based on the output data, whether one or more morphologically abnormal cells are likely to be present in the specimen image.
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G06V 10/80 - Fusion, c. à d. combinaison des données de diverses sources au niveau du capteur, du prétraitement, de l’extraction des caractéristiques ou de la classification
87.
SYSTEMS AND METHODS FOR SHARING HEALTHCARE DATA WITH HEALTHCARE DATA PROCESSORS
A computer implemented method for a data sharing system to share healthcare data from a healthcare data provider with a healthcare data processing application. The method includes identifying one or more healthcare data processor applications, generating and displaying selectable options of the one or more data processor applications at a healthcare data provider, obtaining a selection of the one or more data processor applications from the healthcare data provider, obtaining a data provider/application-specific encryption keyset corresponding to each selected healthcare data processor application, the keyset comprising a private key and a public key, retaining the private key of the data provider/application-specific keyset with a trusted component of the healthcare data provider, and sharing the public key of the data provider/application-specific keyset with the corresponding selected healthcare data processor application.
G16H 40/20 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion ou l’administration de ressources ou d’établissements de soins de santé, p.ex. pour la gestion du personnel hospitalier ou de salles d’opération
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p.ex. pour des dossiers électroniques de patients
H04L 9/30 - Clé publique, c. à d. l'algorithme de chiffrement étant impossible à inverser par ordinateur et les clés de chiffrement des utilisateurs n'exigeant pas le secret
88.
COMPUTER-IMPLEMENTED METHOD FOR DETECTING AT LEAST ONE ANALYTE IN A SAMPLE WITH A LASER DESORPTION MASS SPECTROMETER
A computer-implemented method for detecting at least one analyte in a sample with a laser desorption mass spectrometer (220) is disclosed. The method comprises: a) at least one imaging step comprising imaging at least one reflective target (128) by using at least one imaging device (235), wherein the sample comprising the at least one analyte is applied to the reflective target (128); b) at least one sample recognition step comprising localizing at least one sample re- gion on the reflective target (128); and c) at least one analyte detection step comprising detecting the at least one analyte in the sample using surface assisted laser desorption ionization mass spectrometry (SALDI-MS) with the laser desorption mass spectrometer (220), wherein laser ir- radiation is applied to the reflective target (128) by using at least one laser source (222) of the laser desorption mass spectrometer (220) such that at least one ion of the at least one analyte is generated which is detected by using at least one of a mass analyzing unit (224) or an ion-mobility spectrometry device of the laser de- sorption mass spectrometer (220), wherein the laser irradiation is steered on the localized sample region by using at least one control device (237).
H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules
H01J 49/16 - Sources d'ions; Canons à ions utilisant une ionisation de surface, p.ex. émission thermo-ionique ou photo-électrique
H01J 49/04 - Dispositions pour introduire ou extraire les échantillons devant être analysés, p.ex. fermetures étanches au vide; Dispositions pour le réglage externe des composants électronoptiques ou ionoptiques
Computer-implemented methods for analysing a medical image are provided, the method comprising: obtaining a medical image; inputting the image into a machine learning model, the machine learning model trained with training medical images, by: obtaining a plurality of smaller image segments from the training medical images; obtaining an image embedding for each image segment; and processing the embeddings using one or more attention mechanisms comprising a B-cos transform. Related methods, products and systems are described.
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
An in-vitro diagnostic (IVD) analyzer (200) comprising at least one sensor (212) located in a flow-through sensor path (211) of detecting unit and requiring at least one oxygenated calibration fluid (221', 222') for calibration is herein disclosed. The IVD analyzer (200) further comprises a fluid-supply unit (220) comprising at least one deoxygenated calibration fluid (221, 222), a fluid-selection valve (230) and at least one oxygenation tubing (215, 216) having two ends connected to the fluid-selection valve (230) as a loop, wherein the oxygenation tubing (215, 216) comprises oxygen-permeable walls, and wherein the IVD analyzer (200) further comprises a pump (240) and a controller (250) configured to control the pump (240) and the fluid-selection valve (230) for transporting deoxygenated calibration fluid (221, 222) into the oxygenation tubing (215, 216), to wait a predetermined time required for oxygenation of the deoxygenated calibration fluid (221, 222) via oxygen uptake from ambient air through the tubing walls, and to transport the thereby obtained oxygenated calibration fluid (221', 222') into the sensor path (211) for calibration of the at least one sensor (212). A respective automatic method of calibrating at least one sensor (212) is herein also disclosed.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
G01N 33/96 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir un étalon de contrôle du sang ou du sérum
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Chemical, biological and biochemical preparations for the analysis of biological samples for medical purposes; medical diagnostic assays and reagents for the analysis of biological samples for clinical or medical purposes; diagnostic reagents and preparations for medical purposes; in vitro diagnostic agents for the analysis of biological samples for medical purposes; kits consisting primarily of reagents and diagnostic preparations for clinical and medical diagnostic purposes analyzers for the analysis of biological samples for medical diagnostic purposes
92.
METHOD FOR IMMUNOSENSING ON A LIPID LAYER USING MAGNETIC TUNNEL JUNCTIONS
The present invention relates to diagnostic test and technology. In particular, the present invention relates to a method for determining an analyte suspected to be present in a sample comprising contacting said sample with a sensor element comprising an anchor layer which is present on a solid support, a first binding agent which is capable of specifically binding to the analyte, which is anchored in the anchor layer and which comprises at least one magnetic label, wherein said at least one magnetic label is located within the anchor layer, a second binding agent which is capable of specifically binding to the analyte when bound to the first binding agent and which is immobilized on the solid support, and a magnetic tunnel junction in functional proximity to the second binding agent which generates a signal elicited in proximity to the at least one magnetic label of the first binding agent, for a time and under conditions which allow for specific binding of the analyte suspected to be present in the sample to the first binding agent and specific binding of the second binding agent to the analyte bound to the first binding agent and detecting the formation the complex of first binding agent, analyte and second binding agent based on the signal which is generated by the magnetic tunnel junction whereby the analyte is determined. Moreover, provided is a device for determining an analyte suspected to be present in a sample and the use thereof for determining an analyte suspected to be present in a sample in said sample. Moreover, the present invention contemplates a kit for determining an analyte suspected to be present in a sample.
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
93.
UNIVERSAL CALIBRATION FOR QUANTITATIVE MASS SPECTROMETRY
The present invention relates to a method of determining an analyte in a sample by mass spectrometry (MS), the method comprising (a) admixing a pre-determined amount of internal calibrator to said sample, wherein said internal calibrator comprises at least two non-identical isotopologues of the analyte at predetermined amounts; (b) determining MS signals of ions generated from said analyte (analyte signal) and from said at least two isotopologues (isotopologue signals); (c) providing a calibration based on the analyte signal and the isotopologue signals determined in step (b); and (d) determining said analyte based on the calibration provided in step (c). Further, the present invention relates to devices, systems, and uses related thereto.
G01N 33/74 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des hormones
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules
94.
DIAGNOSTIC DEVICE AND METHOD FOR MONITORING BODY TISSUE OF A PATIENT
A diagnostic device (110) for monitoring at least one body tissue (134) of a patient is disclosed. The diagnostic device (110) comprises: a. at least one bracelet (112) configured to be strapped around a body part (132) of the patient; b. at least one electromechanical actuator (114) configured for actively varying a circumference of the bracelet (112); c. at least one measurement unit (126) configured for determining at least one item of information on an electrical power applied to the electromechanical actuator (114) and at least one item of circumference information on the circumference of the bracelet (112); and d. at least one evaluation unit (128) configured for determining at least one item of information on a status of the body tissue (134) from the item of information on the electrical power applied to the electromechanical actuator (114) and the item of circumference information, wherein the evaluation unit (128) is configured for determining a point of contact at which the circumference of the bracelet (112) corresponds to the circumference of the body part. Further, a method of monitoring at least one body tissue (134) of a patient is disclosed.
A61B 5/107 - Mesure de dimensions corporelles, p.ex. la taille du corps entier ou de parties de celui-ci
A61B 5/05 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/0205 - Evaluation simultanée de l'état cardio-vasculaire et de l'état d'autres parties du corps, p.ex. de l'état cardiaque et respiratoire
95.
HIGHLY WATER-SOLUBLE AND STABLE CHEMOSENSOR FOR CYSTEINE
The present invention relates to chemical probes for the improved detection of cysteine in a test sample, preferably an aqueous test sample, as well as respective uses and kits.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C07C 259/06 - Composés contenant des groupes carboxyle, un atome d'oxygène d'un groupe carboxyle étant remplacé par un atome d'azote, cet atome d'azote étant lié de plus à un atome d'oxygène et ne faisant pas partie de groupes nitro ou nitroso sans remplacement de l'autre atome d'oxygène du groupe carboxyle, p.ex. acides hydroxamiques ayant des atomes de carbone de groupes hydroxamique liés à des atomes d'hydrogène ou à des atomes de carbone acycliques
96.
AUTOMATED ANALYSIS DEVICE, AND METHOD FOR OPERATING AUTOMATED ANALYSIS DEVICE
This automated analysis device comprises an analyzing unit 40 for analyzing a sample, and a control device 20 for controlling operations of each mechanism of the analyzing unit 40, wherein the control device 20 calculates a waiting time that a user should wait until the sample or a consumable required to analyze the sample is replaced, on the basis of a time at which the sample or the consumable is to be used last, in an analysis schedule created at a time point at which a replacement request for the sample or the consumable is accepted. By this means, the present invention provides an automated analysis device, and a method for operating the automated analysis device, capable of improving work efficiency.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
The present invention relates to reagents which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said reagents.
C07D 249/06 - Triazoles-1, 2, 3; Triazoles-1, 2, 3 hydrogénés avec des radicaux aryle liés directement aux atomes du cycle
C07D 203/04 - Composés hétérocycliques contenant des cycles à trois chaînons ne comportant qu'un seul atome d'azote comme unique hétéro-atome du cycle non condensés avec d'autres cycles
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
A healthcare computer system, the computer system comprising a communications module, a string generation module, a one-way function module and an anonymised data generation module. The communications module is configured to receive one or more healthcare data packets, each healthcare data packet including: data pertaining to one or more medical analytical tests performed on a sample; a sample identifier, identifying the sample; and a timestamp, indicating when the analytical test(s) was performed. The string generation module is configured to generate a string based on the sample identifier and the timestamp. The one-way function module is configured to apply a one-way function to the generated string to generate an anonymised sample identifier. The anonymised data generation module is configured to generate an anonymised healthcare data packet including the data pertaining to the one or more medical analytical tests and the anonymised sample identifier.
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p.ex. pour des analyses d’échantillon de patient
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p.ex. pour des dossiers électroniques de patients
A healthcare data management system for managing processing capacity in a healthcare data management system. The healthcare data management system includes: one or more processing pipelines connected to one or more of the medical devices and configured to receive medical data therefrom, wherein each processing pipeline comprises a plurality of processing stages arranged in series and configured to perform respective operations on the received healthcare data, wherein each processing stage is implemented on a stateless atomic processing unit; a healthcare middleware is configured to receive processed data therefrom and to provide the processed data to a healthcare information management system; a performance management unit is configured to monitor a performance of the or each processing pipeline and adjust a number of stateless atomic processing units implementing a given processing stage within a given processing pipeline based on the monitored performance.
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p.ex. pour des analyses d’échantillon de patient
G06F 9/48 - Lancement de programmes; Commutation de programmes, p.ex. par interruption
G16H 40/20 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion ou l’administration de ressources ou d’établissements de soins de santé, p.ex. pour la gestion du personnel hospitalier ou de salles d’opération
100.
MONITORING DEVICE FOR MONITORING A SAMPLE HANDLING SYSTEM
A monitoring device for monitoring a sample handling system comprising:
a sliding unit comprising a sliding surface, wherein the sliding unit is configured for sliding over a sample transport device of the sample handling system; and
an imaging streaming unit comprising s camera, wherein the camera is configured for capturing a plurality of images, wherein the imaging streaming unit comprises an imaging communication interface for providing the plurality of captured images to a transport control system of the sample handling system.
A monitoring device for monitoring a sample handling system comprising:
a sliding unit comprising a sliding surface, wherein the sliding unit is configured for sliding over a sample transport device of the sample handling system; and
an imaging streaming unit comprising s camera, wherein the camera is configured for capturing a plurality of images, wherein the imaging streaming unit comprises an imaging communication interface for providing the plurality of captured images to a transport control system of the sample handling system.
Further disclosed is a transport control system for controlling transport of a plurality of sample container holders of a sample handling system, a sample handling system for handling a plurality of samples, a method for identifying an obstacle, a method for determining a distance between the obstacle and a monitoring device and a method for controlling a monitoring device and computer programs and computer-readable storage media for performing the methods.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
G01N 35/02 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse
G06T 7/55 - Récupération de la profondeur ou de la forme à partir de plusieurs images
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
